![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
P Blanchet, PJ Bedard, DR Britton and JW Kebabian
Centre de recherche en neurobiologie, Hopital de l'Enfant-Jesus, Quebec, Canada.
The motor effects of selective D-1 dopamine receptor stimulation in Parkinson's disease have been explored in a limited number of studies with partial D-1 agonists only and the results were unsatisfactory. Four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed parkinsonian monkeys already exhibiting levodopa- and dopamine agonist-induced dyskinesia received selective D-1 agonists ([2,3,4,5-tetrahydro-7-8- dihydroxy-1-phenyl-1-H-3-benzazepine- HCI] (SKF 38393), [(+-)6-chloro- 7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro- 1H-3-benzazepine hydrobromide] (SKF 82958), [(1R, 3S)3-(1'-adamantyl)-1-aminomethyl-3,4- dihydro-5,6- dihydroxy-1H-2-benzopyran hydrochloride] (A-77636) and [(- )-(6aR)(12bR)-4,6,6a,7,8,12b-hexahydro-7-methyli ndolo (4,3-ab)- phenanthridine] (CY 208-243)) to compare these drugs with selective D-2 agonists (LY 171555, (+)-4-propyl-9- hydroxynaphthoxazine and bromocriptine) and levodopa in terms of antiparkinsonian efficacy and side effects. The D-1 class of compounds was as efficacious as the D-2 agents in alleviating parkinsonism in these animals. However, D-1 agonists were, in general, less likely to reproduce dyskinesia. In addition, D-1 agonists occasionally improved motor symptoms without concomitant dyskinesia, unlike D-2 agonists or levodopa (which always produced some dyskinesia with improvement in motor function). These preliminary results do not support the hypothesis that preferential D-1 receptor stimulation facilitates dyskinesia in primates.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  P. Jenner The MPTP-treated primate as a model of motor complications in PD: Primate model of motor complications Neurology, September 23, 2003; 61(90063): S4 - 11. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. Stocchi, S. Ruggieri, L. Vacca, and C. W. Olanow Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease Brain, September 1, 2002; 125(9): 2058 - 2066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Jenner Pharmacology of dopamine agonists in the treatment of Parkinson's disease Neurology, February 1, 2002; 58(90001): S1 - 8. [Abstract] [Full Text]
|
|
|
|
|
|
C. W. Olanow, R. L. Watts, and W. C. Koller An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment Neurology, June 12, 2001; 56(suppl_5): S1 - S88. [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Gulwadi, C. D. Korpinen, R. B. Mailman, D. E. Nichols, S.-Y. Sit, and M. T. Taber Dinapsoline: Characterization of a D1 Dopamine Receptor Agonist in a Rat Model of Parkinson's Disease J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 338 - 344. [Abstract] [Full Text]
|
|
|
|
|
|
A. J. Manson, H. Hanagasi, K. Turner, P. N. Patsalos, P. Carey, N. Ratnaraj, and A. J. Lees Intravenous apomorphine therapy in Parkinson's disease: Clinical and pharmacokinetic observations Brain, February 1, 2001; 124(2): 331 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Rascol, J. G. Nutt, O. Blin, C. G. Goetz, J. M. Trugman, C. Soubrouillard, J. H. Carter, L. J. Currie, N. Fabre, C. Thalamas, et al. Induction by Dopamine D1 Receptor Agonist ABT-431 of Dyskinesia Similar to Levodopa in Patients With Parkinson Disease Arch Neurol, February 1, 2001; 58(2): 249 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Goulet and B. K. Madras D1 Dopamine Receptor Agonists Are More Effective in Alleviating Advanced than Mild Parkinsonism in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Monkeys J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 714 - 724. [Abstract] [Full Text]
|
|
|
|
|
|
R. Grondin, P. J. Bedard, A. H. Tahar, L. Gregoire, A. Mori, and H. Kase Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys Neurology, May 1, 1999; 52(8): 1673 - 1673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Grondin, V. D. Doan, L. Gregoire, and P. J. Bedard D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys Neurology, March 1, 1999; 52(4): 771 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Blanchet, S. Konitsiotis, and T. N. Chase Motor Response to a Dopamine D3 Receptor Preferring Agonist Compared to Apomorphine in Levodopa-Primed 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Monkeys J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 794 - 794. [Abstract] [Full Text]
|
|
|
|
|
|
K. E. Asin, E. F. Domino, A. Nikkel, and K. Shiosaki The Selective Dopamine D1 Receptor Agonist A-86929 Maintains Efficacy with Repeated Treatment in Rodent and Primate Models of Parkinson's Disease J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 454 - 459. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
